EVH vs TDOC

For growth investors, Teladoc Health, Inc.

(TDOC) is the stronger pick with -1. 5% revenue growth year-over-year, versus -26. 6% for Evolent Health, Inc. (EVH). Analysts rate Evolent Health, Inc. (EVH) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Evolent Health, Inc.

(EVH) delivered a total return of -78. 4%, compared to -95. 4% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: TDOC returned -41. 1% versus EVH's -63. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Evolent Health, Inc.

(EVH) is the lower-risk stock at 1. 21β versus Teladoc Health, Inc. 's 1. 91β — meaning TDOC is approximately 58% more volatile than EVH relative to the S&P 500. On balance sheet safety, Teladoc Health, Inc. (TDOC) carries a lower debt/equity ratio of 75% versus 2% for Evolent Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Teladoc Health, Inc.

(TDOC) is pulling ahead at -1. 5% versus -26. 6% for Evolent Health, Inc. (EVH). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -525. 9% for Evolent Health, Inc.. Over a 3-year CAGR, EVH leads at 11. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Teladoc Health, Inc.

(TDOC) is the more profitable company, earning -7. 9% net margin versus -28. 5% for Evolent Health, Inc. — meaning it keeps -7. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EVH leads at -0. 2% versus -10. 4% for TDOC. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for EVH: 49.

1% to $6. 38.

In this comparison, EVH (2.

3% yield) pays a dividend. TDOC does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Evolent Health, Inc.

(EVH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), 2. 3% yield). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EVH: -63. 6%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

EVH pays a dividend while TDOC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.